Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-FR Version v1-EN
Language French English
Date Updated 2021-10-07 2021-05-25
Drug Identification Number 02459760 02459760
Brand name GLYXAMBI GLYXAMBI
Common or Proper name GLYXAMBI 25/5MG 3X10S GLYXAMBI 25/5MG 3X10S
Company Name BOEHRINGER INGELHEIM (CANADA) LTD LTEE BOEHRINGER INGELHEIM (CANADA) LTD LTEE
Ingredients LINAGLIPTIN EMPAGLIFLOZIN LINAGLIPTIN EMPAGLIFLOZIN
Strength(s) 5MG 25MG 5MG 25MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 3X10 BLISTER PACK 3X10 BLISTER PACK
ATC code A10BD A10BD
ATC description BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date 2021-10-31 2021-10-29
Actual discontinuation date
Remaining supply date 2021-10-31 2021-10-29
Discontinuation status To be discontinued To be discontinued
Discontinuation decision reversal no no
Information on remaining supply
Company comments
Health Canada comments